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Objectives: A binary reimbursement prediction model was previously developed 
based on a dataset of submissions to the Scottish Medicines Consortium (SMC) 
between 2006 and 2014. The objective of this study is to build on the previous model 
by identifying factors that influence the different levels of SMC recommendation, 
defined as “recommend”, “restrict” or “not recommend” pharmaceutical technolo-
gies for use in Scotland. MethOds: Univariate and multivariate ordered logistic 
regression analyses were performed to assess the impact by means of odds ratios 
(OR) of the submitted evidence to the SMC on the decision. The proportional odds 
assumption underlying the current approach was tested. Results: Out of 463 appli-
cations, 115 received positive recommendation (25%), 150 received restricted recom-
mendation (32%) and 198 (43%) were not recommended. Univariate analyses showed 
that 14 variables significantly affected the SMC decision. The multivariate analyses 
showed significant associations (p≤ 0.05) between the SMC decision and several 
variables, including: (1) a product demonstrating cost savings and QALY gains 
[OR= 6.11], (2) a product not being cost-effective (ICER≥ £30,000/QALY) [OR= 0.50], (3) 
a non-superior efficacy outcome versus placebo [OR= 0.15], (4) the product’s thera-
peutic indication (nervous system [OR= 0.51], blood forming organs [OR= 2.29]), (5) 
whether the product was indicated for non-chronic use [OR= 1.48] and (6) whether 
the submission was performed by a big company [OR= 1.86]. The proportional odds 
assumption was not violated, proving the appropriateness of the current model. The 
present model yielded similar results with the previously developed binary logistic 
one, further ensuring face validity, yet this approach is considered to better fit the 
multidimensional nature of SMC’s decision and increase the predictive power of 
the model. cOnclusiOns: This study identified superior efficacy using an active 
comparator as well as a beneficial cost-effectiveness outcome to increase the likeli-
hood of receiving a positive recommendation by the SMC.
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Objectives: The entrenched positioning of biologics to treat moderate-to-severe 
rheumatoid arthritis (RA) has generated a lucrative market. However, amid ongo-
ing economic constraints, the EU5 (France, Germany, Italy, Spain, and the UK) must 
tighten their health care belts. As biosimilars versions of key brands appear on 
the horizon, this study explored the expected impact of these cheaper options 
on reimbursement and prescribing for RA in each country. MethOds: Across the 
EU5, 254 rheumatologists were surveyed regarding their views on biosimilars for 
RA and on current and expected prescribing patterns. In addition, 15 payers who 
influence reimbursement at national or regional level were interviewed. Results: 
Considering 54-week Phase III data, ≥ 80% of surveyed rheumatologists in each coun-
try believe CT-P13 (biosimilar infliximab) has similar efficacy to branded Remicade; 
however, respondents are less confident in the biosimilar’s safety. Furthermore, 
> 80% of respondents in most countries are willing to prescribe biosimilars of inf-
liximab, and of etanercept and rituximab, though largely not before branded biolog-
ics. Unsurprisingly, given likely price discounts, interviewed payers will somewhat 
encourage biosimilar uptake. However, excluding those in Germany, consensus is 
that discounts offered on biosimilars will not significantly impact their budgets. 
German payers, however, report that additional rebates to statutory insurers are 
expected; they admit to financial incentives for physicians to prescribe rebated 
drugs, thus manufacturers may consider robust uptake will compensate for hefty 
discounts. cOnclusiOns: Available data have inspired prescriber confidence in 
biosimilar efficacy, although safety concerns, likely stemming from complex bio-
similar manufacturing and lack of long-term safety data, will ensure continued 
brand uptake, at least initially. Furthermore, the expected modesty of biosimilar 
discounts in most countries will somewhat curb payer policy promoting use of such 
agents. However, as prescribers become more familiar with biosimilars, and, as the 
full extent of cost savings are revealed, increasing uptake of biosimilars is probable.
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Objectives: Incentives are offered to pharmaceutical companies in order to 
increase the number of treatments for patients with rare diseases. As a conse-
quence, a number of new drugs have been introduced on the market—drugs that 
often fail to meet traditional cost-effectiveness criteria. This study aims to inves-
tigate if there are societal preferences for treating patients with rare diseases dif-
ferently in priority setting situations compared with common diseases. Moreover, 
psychological mechanisms that potentially could explain such preferences are 
explored. MethOds: A postal questionnaire in three versions was sent out to a 
representative sample of the general Swedish population. Respondents were asked 
to choose to give treatment to a patient with a rare or a common disease in eight 
different scenarios. Rarity of the disease, different alternative costs, and group/
individual level decisions was investigated. Psychological aspects in the presented 
scenaros that varied between subjects was related to proportion dominance, the 
identifiability of the patient, pseudo-inefficacy and if the scenario was expressed in 
priority or rationing terms. Results: Response rate was 41 % (n= 1239). For equal 
cost scenarios, 42.3 % were indifferent between the rare and the common group, 
23.9 % chose to prioritize the rare disease and 33.4 % the common disease. When 
questions were framed to be on an individul as opposed to a group level repond-
ents were significantly (p< .001) more likely to be indifferent. Proportion dominance 
increased individuals’ preferences to prioritize rare diseases (p< .001). Identifiability 
and pseudo-inefficacy had no major effect on respondents’ choices. cOnclusiOns: 
All else equal we see no strong support that a societal preference for rarity exists. 
However, we observe psychological effects influencing the judgments individuals 
make when setting priorities related to rare diseases. Whether or not these should 
quantify the value of using stratified information over population-based informa-
tion. Results: The incremental cost-effectiveness ratio (ICER) of CT versus X-ray 
was $31,942 per QALY, for the “average” trial patient, indicating that CT would be 
the preferred option at a cost-effectiveness threshold of $50,000 per QALY. However, 
when stratified into quintiles, CT is dominated for the lowest risk quintile (i.e., X-ray 
is the preferred option for quintile 1) and CT is preferred for higher risk groups (quin-
tiles 2 to 5). The EVIC was calculated at around $180 per person for cost-effectiveness 
thresholds of $50,000 per QALY and higher. cOnclusiOns: Tailoring screening 
strategies to avoid CT scan in the lowest risk quintile of patients appears to be a 
superior strategy compared to population-wide CT scan screening, although results 
were sensitive to the cost-effectiveness threshold and the level of granularity of the 
analysis. This study shows the value of considering the risk-based heterogeneity 
of cost-effectiveness in clinical guideline recommendations and policy decisions.
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Objectives: Self-monitoring of blood glucose (SMBG) may improve diabetes man-
agement. We analyzed the effect of SMBG on glycemic control, clinical outcomes 
and health care costs among insulin-users diabetic patients in a clinical practice 
setting. MethOds: A retrospective analysis using data from the administrative 
databases, clinical registries containing laboratory results and medical devices data-
bases including SMBG strips data of two Italian Local Health Units was performed. 
Insulin-users were defined if they had at least one prescription of insulin agents from 
November, 2009 and April, 2011. The first prescription was selected as index-date. 
Patients were divided into two groups based on testing frequency of SMBG during 
the 18 months after the index-date: no test strip claims (no SMBG use) and more 
than two test strips per day. We calculated incidence rates to estimate the risk for 
fasting blood glucose levels < 70 mg/dl and for diabetes-related hospitalizations or 
death occurrence during the 18-months follow-up period. Total annual costs included 
hypoglycemic therapy and the direct costs due to diabetes-related hospitalizations 
and outpatient services. Results: We identified 394 insulin-users patients with no 
SMBG use and 1350 with SMBG performed more than twice per day. Compared with 
non-SMBG use group, patients using SMBG showed a significant reduced risk of glu-
cose levels < 70 mg/dl (unadjusted rate was 10,6 vs 27,3 per 100 person-years, p< 0.001) 
and of diabetes-related hospitalizations or death (30,0 vs 60,8 per 100 person-years, 
p< 0.001). The higher hospitalization rate resulted in higher hospitalization costs per 
patient (€ 2.419 vs € 1.512 of those with SMBG use) and consequently higher total 
annual direct costs per patient (€ 3.060 vs € 2.738 of those using SMBG). cOnclusiOns: 
Results indicate that patients using SMBG, compared with non-SMBG patients, are 
associated with better glycemic control and reduced risk of diabetes-related hospi-
talizations and consequently with lower overall total annual cost per patient.
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Objectives: Anxiety and mood disorders are highly prevalent in Primary Care but 
research shows that general practitioners (GPs) fail to diagnose up to half of cases. In 
this study we try to determine the diagnostic accuracy of GPs’ diagnoses of anxiety 
disorders with and without any help from diagnostic (assisted vs unassisted diagno-
sis). MethOds: We searched for articles published from January 1980 to June 2014 in 
7 databases. We included studies in English, Spanish, French, and German reporting 
the ability of GPs to identify any anxiety disorder (DSM III/ IV/ IV-TR diagnostic crite-
ria) in Primary Care community samples. We excluded studies from general popula-
tion and those addressing specific physical or mental disorders, along with vignette 
and case-series studies. Two authors independently performed abstract and full-text 
reviews and data extraction. Study was assessed with the QUADAS-2. Coupled forest 
plots summarized estimated studies’ sensitivity and specificity and 95% confidence 
intervals. We fitted random-effects meta-analysis models and undertook a bivari-
ate meta-analysis to construct a summary Receiver Operator Characteristic Curve 
(sROC). Results: From a total 17.964 detected papers, 443 were included for full text 
review. So far, we have analyzed 111 papers, out of which 8 studies were included 
with N= 3608 patients with pooled anxiety prevalence 26% (CI= 25-27%). Preliminary 
results shows an overall ROC curve with lower GP diagnostic accuracy when per-
forming unassisted diagnoses for a total diagnostic accuracy 80% (CI= 79.4-80.1) with 
overall sensitivity= 49% (CI= 45-53), and Specificity = 92% (CI= 90-94). GP’s accuracy 
was higher with assisted diagnoses (86.7%, CI= 85%-89%) than unassisted diagnoses 
(45.5%; CI= 43.7%-47.3%). Specificity was lower in assisted (89.15%; CI= 87.9-90.4) 
than unassisted diagnosis (92.5%; CI= 91.9-93.1). cOnclusiOns: Low diagnostic 
sensitivity might hinder the adequate detection and management of anxiety in 
primary care. Results suggest that detection might be improved by using diagnostic 
tools. Results for all included articles will be presented.
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submissions. BCVA (Best Corrected Visual Acuity) scores were available for limited 
number of East Asian patients (N= 35) from a phase III, 12-month, randomized, 
double-masked, multicenter, active-controlled study (RADIANCE). To populate a 
transition probability matrix with 8 health states based on BCVA scores, a statisti-
cal model was proposed to simulate a larger hypothetical patient cohort. A mixed-
effect model was fitted on the observed BCVA scores with baseline BCVA score as 
covariate, patients as random effect and an autoregressive AR(1) error correlation 
structure amongst the repeated observations. This model was used to simulate a 
patient cohort of 35,000. Transition probabilities were estimated using traditional 
division by row sum method. Several simulations were run to confirm consistency 
of results. Results: From baseline to month 3, percentage of patients with BCVA 
≥ 20 letters gain was 22.45% in observed data vs 22.49% in simulated data, and 
percentage of patients with BCVA ≥ 20 letters loss was 0.008% in observed data 
vs 0.009% in simulated data. BCVA change from baseline to month 3 in simulated 
data (mean= 13.3, SD= 8.3) was verified with that of the observed data (mean= 13.3, 
SD= 8.8). cOnclusiOns: Transition probability estimation by simulation from a 
fitted statistical model can overcome the challenges posed by small patient cohorts 
and multiple state transitions.
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Objectives: In cost-effectiveness analysis (CEA), mean survival difference (QALY-
adjusted) over a lifetime horizon is required. Parametric models are necessary to 
extrapolate survival outcomes beyond the Randomized Controlled Trial (RCT) period. 
However, mean survival is very sensitive to the assumed model and different mean 
survival times may result from models fitting similarly well to the RCT data. We 
investigate the idea that other sources of information, external to the trial data, 
could be used to inform model choice and estimation. MethOds: We explored 
various survival models and we show how external information can be used to 
put constraints on spline-based survival models. We illustrate with a Technology 
Appraisal (TA) of head and neck cancer where RCT evidence had 5 year follow up. 
A US cancer database (SEER), general population data and expert opinion were 
used to impose constraints on overall survival, conditional survival, and hazard 
ratio. RCT and external data were fitted simultaneously within a Bayesian frame-
work. Results: Standard survival time distributions were insufficiently flexible 
to simultaneously fit both the RCT data and general population constraints. Spline 
models were sufficiently flexible, although there were difficulties choosing initial 
values. A good fit to all sources of internal and external evidence was achieved 
within one integrated model using splines on the log hazard. Cetuximab in addi-
tion to radiotherapy improves the expected survival by 4.7 months [95% CrL: 0.4; 
9.1] compared to radiotherapy alone. cOnclusiOns: The method enabled us to 
estimate models consistent with all evidence. Clinical knowledge is essential to 
guide the interpretation of the external data sources. The method could be used 
to analyze other RCTs on other cancers and with other treatments. Other flexible 
models than splines could be investigated.
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Objectives: Health technology assessment of treatments often requires estimates 
of their survival curves. Individual patient data (IPD) are often unavailable and the 
survival curves are usually calculated by fitting a nonlinear least squares (NLS) 
model directly to Kaplan Meier plots provided in the published literature. This 
method does not account for the uncertainty associated with the Kaplan Meier 
curve and can lead to biased estimates. Although the IPD are often missing, the 
Kaplan Meier curve itself can be digitised and used to approximate what the origi-
nal IPD could have been. MethOds: We simulated trial IPD data from different 
survival distributions in order to assess the accuracy of the IPD reconstruction 
methods. The assessment of accuracy is made at multiple stages and ultimately 
the effects on the incremental cost effectiveness ratio (ICER) estimates are com-
pared. To do so, a simple cost-effectiveness model was developed, assuming two 
health states (alive and dead), and assigning costs (£1,000 per month plus drug 
costs) and a utility score (0.70) to generate ICERs. Two additional methods to curve 
fitting are compared against the NLS approach – those suggested by Guyot (G), and 
by Hoyle & Henley (HH). Results: We find that the methods differ in accuracy at 
each of the following two stages; (a) model selection via the AIC and secondly (b) 
survival model parameter estimation. When an underlying Weibull function was 
assumed, the ‘true’ ICER should be £28,924, compared against £31,182 £33,449 and 
£31,650 for the NLS, HH and G methods respectively. When an underlying loglogistic 
function was assumed, the NLS, HH and GG methods produced ICERs of £26,507, 
£25,559 and £25,857, compared to a ‘true’ ICER of £25,779. cOnclusiOns: These 
findings suggest that inherent biases may be apparent in each of the approaches, 
and these may manifest themselves differently, depending upon the ‘true’ shape 
of the underlying data.
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be viewed as biases or an expression of true preferences is a matter for further 
discussion.
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Objectives: The first infliximab biosimilars reached the EU in September 2013, 
representing the first biosimilar monoclonal antibodies (mAbs) to obtain EMA 
approval. Although commercialization in the major European markets will only 
start in February 2015, payers in Nordic and Eastern European countries have already 
faced the dilemma of striking the balance between potential savings accrued from 
use of less expensive infliximab biosimilars and demands for robust proof of clinical 
efficacy and safety. This work identifies payers’ evidence expectations, their reli-
ance on regulators’ decisions and how potential savings can influence access and 
recommendations to target patient populations. MethOds: Exploratory qualita-
tive primary research with payers (N= 12) from France, Italy, Spain, UK, Germany 
and Netherlands. Collection of data about the current and future attitudes towards 
biosimilar health technology assessments at the national and, if applicable, local 
levels will be conducted, as well as perceived price and access trade-offs. Results: 
(1) Payers will mainly defer to the EMA the decision on acceptability of biosimilar 
indication extrapolation (indications where biosimilars do not have direct clinical 
trial data); (2) It is understood that mAb biosimilar clinical development is more 
onerous and costly than small molecule generics, thus payers do not expect the 
same magnitude of discounts offered vs. originator; (3) Although eager to obtain 
savings from broad patient populations, payers will not implement pharmacy-level 
substitution or enforce biosimilar use in originator-experienced patients; (4) Use in 
naïve patients will be recommended in most markets. cOnclusiOns: Across the 
EU5, payers acknowledge physicians’ concerns over long term safety and efficacy 
of biosimilars. Nonetheless, they will rely on the regulators evaluations and expert 
panels to justify implementing recommendations, and in some markets, restrict 
formularies based exclusively on cost. Moreover, they have conservative discount 
expectations at launch, with the long-term aim of incentivizing further competition 
from other biosimilar manufacturers.
researCH on metHods – modeling studies
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Objectives: Patient-level simulation models provide increased flexibility to over-
come the limitations of cohort-based approaches in health-economic analysis. 
However, computational requirements of reaching convergence is a notorious 
barrier. The objective was to assess the impact of using quasi-monte carlo simu-
lation (QMCS) and variance reduction techniques (VRTs) on computational require-
ments. MethOds: A recently published discrete event simulation model assessing 
the cost-effectiveness of an adjunctive antipsychotic treatment for depression was 
used. The following VRTs were implemented: antithetic variables, common random 
numbers (CRN) and the combination (Anti_CRN). In addition, QMCS was conducted 
using the Sobol low discrepancy sequence. The minimal number of patients required 
to reach equal precision as the reference situation of 1,000,000 simple monte carlo 
simulations (MCS) was recorded. Precision was defined by the standard error (SE) 
of the incremental net monetary benefit (INMB) at a willingness to pay of € 20,000 
per quality adjusted life year gained. VRT simulations were replicated 100 times. 
INMB estimates were compared with the reference situation using mean squared 
error (MSE), mean absolute error (MAE) and percentage of under- and overesti-
mations. Results: Reference INMB (SE) was € 1,413 (76). The average number of 
patients required to reach reference precision were 929,628, 35,692, 41,683 and 
36,803 for antithetic variables, CRN, Anti_CRN and Sobol respectively. This implied 
a computation time reduction ranging between 7% and 96% compared to simple 
MCS. MSE was 346,036, 16,314, 155,950 and 7,475 respectively. MAE was 588, 105, 
387 and 86 respectively. Antithetic variables and Anti_CRN structurally underes-
timated INMB (99% and 100%). CRN marginally overestimated INMB in 76 replica-
tions. cOnclusiOns: QMCS and VRT reduce computational requirements in terms 
of simulated patients and computational time up to 96%, enhancing the practical 
feasibility of patient-level simulation models. This particularly applies to Sobol and 
CRN. Antithetic variables should be used with caution and its structural bias war-
rants further research.
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Objectives: Markov model is one of the most used decision analytic models in 
health care. Transitions between health states in a Markov model is driven by tran-
sition probability matrix. When the number of patients and observed transitions 
are limited, transition probability estimation becomes challenging. The objective 
of this exercise is to demonstrate how transition probabilities can be estimated by 
simulating data from a statistical model fitted to patient-level data. MethOds: 
An economic model for ranibizumab in mCNV secondary to pathological myopia 
(submitted to NICE in June 2013) was adapted for forthcoming Asian reimbursement 
